Tracing the HIV-1 subtype B mobility in Europe:a phylogeographic approach by Paraskevis, Dimitrios et al.
  
 University of Groningen
Tracing the HIV-1 subtype B mobility in Europe
Paraskevis, Dimitrios; Pybus, Oliver; Magiorkinis, Gkikas; Hatzakis, Angelos; Wensing,






IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2009
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Paraskevis, D., Pybus, O., Magiorkinis, G., Hatzakis, A., Wensing, A. M. J., de Vijver, D. A. V., ... SPREAD
Programme (2009). Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach.
Retrovirology, 6(49), [49]. https://doi.org/10.1186/1742-4690-6-49
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the




Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic 
approach
Dimitrios Paraskevis*1,2, Oliver Pybus3, Gkikas Magiorkinis2, 
Angelos Hatzakis2, Annemarie MJ Wensing4, David A van de Vijver5, 
Jan Albert6,7, Guiseppe Angarano8, Birgitta Åsjö9, Claudia Balotta10, 
Enzo Boeri11, Ricardo Camacho12, Marie-Laure Chaix13, Suzie Coughlan14, 
Dominique Costagliola15, Andrea De Luca16, Carmen de Mendoza17, 
Inge Derdelinckx18, Zehava Grossman19, Osama Hamouda20, 
IM Hoepelman21, Andrzej Horban22, Klaus Korn23, Claudia Kücherer20, 
Thomas Leitner6,7, Clive Loveday24, Eilidh MacRae25, I Maljkovic-Berry6,7, 
Laurence Meyer25, Claus Nielsen26, Eline LM Op de Coul27, 
Vidar Ormaasen28, Luc Perrin29, Elisabeth Puchhammer-Stöckl30, 
Lidia Ruiz31, Mika O Salminen32, Jean-Claude Schmit33, Rob Schuurman4, 
Vincent Soriano17, J Stanczak22, Maja Stanojevic34, Daniel Struck33, 
Kristel Van Laethem1, M Violin10, Sabine Yerly29, Maurizio Zazzi35, 
Charles A Boucher4,5, Anne-Mieke Vandamme1 for the SPREAD Programme
Address: 1Katholieke Universiteit Leuven, Rega Institute for Medical research, Minderbroederstraat 10, B-3000 Leuven, Belgium, 2National 
Retrovirus Reference Center, Department of Hygiene Epidemiology and Medical Statistics, Medical School, University of Athens, M. Asias 75, GR-
11527, Athens, Greece, 3Department of Zoology, University of Oxford, South Parks Road, Oxford, OX1 3PS, UK, 4University Medical Center 
Utrecht, Department of Virology, G04.614, Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands, 5Department of Virology, Erasmus MC, 
University Medical Centre, Postbus 2040 3000 CA Rotterdam, the Netherlands, 6Department of Microbiology, Tumor and Cellbiology, Karolinska 
Institutet, SE 171 77 Stockholm, Sweden, 7Dept of Virology, Swedish Institute for Infectious Disease Control, SE-171 82 Solna, Sweden, 
8University of Foggia, Clinic of Infectious Diseases, Ospedali Riuniti – Via L. Pinto 71100 Foggia, Italy, 9Center for Research in Virology, University 
of Bergen, Bergen High Technology Center, N-5020 Bergen, Norway, 10University of Milano, Institute of Infectious and Tropical Diseases, Via Festa 
del Perdono 7, 20122 Milano, Italy, 11Diagnostica and Ricerca San Raffaele, Centro San Luigi, I.R.C.C.S. Istituto Scientifico San Raffaele, Milan, 
Italy, 12Universidade Nova de Lisboa, Laboratorio de Virologia, Rua da Junqueira 96 1349-008 Lisboa, Portugal, 13EA 3620, Universite Paris 
Descartes, Virologie, CHU Necker, Paris France, 14National Virus Reference Laboratory, University College, Dublin, Ireland, 15INSERM U263 et 
SC4, Faculté de médecine Saint-Antoine, Université Pierre et Marie Curie, 27 rue de Chaligny, F-75571 Paris, France, 16Department of Infectious 
Diseases, Catholic University, L.go A. Gemelli, 8 00168 Rome, Italy, 17Hospital Carlos III, Hospital Carlos III, Madrid, Spain, 18Internal Medicine, 
UZ Leuven, Belgium, 19National. HIV Reference Lab, Central Virology, Public Health Laboratories, MOH Central Virology, Sheba Medical Center, 
2 Ben-Tabai Street, Israel, 20Robert Koch Institut (RKI), Nordufer 20, 13353 Berlin, Germany, 21University Medical Center Utrecht, Department of 
Internal Medicine and Infectious Diseases F02.126, Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands, 22Hospital for Infectious Diseases, 
Center for Diagnosis & Therapy Warsaw 37, Wolska Str. 01-201 Warszawa, Poland, 23University of Erlangen, Schlossplatz 4, D-91054 Erlangen, 
Germany, 24ICVC Charity Laboratories, 3d floor, Apollo Centre Desborough Road High Wycombe, Buckinghamshire, HP11 2QW, UK, 25Inserm, 
U822, Le Kremlin-Bicêtre, F-94276, France, 26Statens Serum Institut Copenhagen, Retrovirus Laboratory, department of virology, building 87, 
Division of Diagnostic Microbiology 5, Artillerivej 2300 Copenhagen, Denmark, 27Centre for Infectious Disease Control (Epidemiology & 
Surveillance), National Institute for Public Health and the Environment (RIVM), 3720 BA Bilthoven, the Netherlands, 28Ullevaal University 
Hospital, Department of Infectious Diseases Kirkeveien 166, N-0407 Oslo, Norway, 29Laboratory of Virology, Geneva University Hospital and 
University of Geneva Medical School, Geneva, Switzerland, 30Institute of Virology, Medical University Vienna, Kinderspitalgasse 15, Vienna, 
Austria, 31IrsiCaixa Foundation, Hospital Germans Trias i Pujol, Ctra. de Canyet s/n, 08916 Badalona (Barcelona), Spain, 32National Public Health 
Institute, HIV laboratory and department of infectious disease epidemiology, Mannerheimintie 166, FIN-00300 Helsinki, Finland, 33Centre 
Hospitalier de Luxembourg, Retrovirology Laboratory, National service of Infectious Diseases, 4 Rue Barblé, L-1210, Luxembourg, 34University of 
Belgrade School of Medicine, Institute of Microbiology and Immunology Virology Department, Dr Subotica 1, 11000 Belgrade, Serbia and 
35Section of Microbiology, Department of Molecular Biology, University of Siena, Italy
Email: Dimitrios Paraskevis* - dparask@cc.uoa.gr; Oliver Pybus - oliver.pybus@zoo.ox.ac.uk; Gkikas Magiorkinis - gmagi@med.uoa.gr; 
Angelos Hatzakis - ahatzak@med.uoa.gr; Annemarie MJ Wensing - A.M.J.Wensing@umcutrecht.nl; David A van de 
Vijver - d.vandevijver@erasmusmc.nl; Jan Albert - jan.albert@smi.ki.se; Guiseppe Angarano - g.angarano@unifg.it; 
Birgitta Åsjö - Birgitta.Asjo@gades.uib.no; Claudia Balotta - claudia.balotta@unimi.it; Enzo Boeri - boeri.enzo@hsr.it; 
Ricardo Camacho - ricardojcamacho@sapo.pt; Marie-Laure Chaix - marie-laure.chaix@nck.ap-hop-paris.fr; 
Suzie Coughlan - suzie.coughlan@ucd.ie; Dominique Costagliola - dominique.costagliola@ccde.chups.jussieu.fr; Andrea De Page 1 of 11
(page number not for citation purposes)
Retrovirology 2009, 6:49 http://www.retrovirology.com/content/6/1/49Luca - andrea.deluca@rm.unicatt.it; Carmen de Mendoza - cmendoza@teleline.es; Inge Derdelinckx - inge.derdelinckx@uz.kuleuven.ac.be; 
Zehava Grossman - Zehava.Grossman@sheba.health.gov.il; Osama Hamouda - HamoudaO@rki.de; 
IM Hoepelman - I.M.Hoepelman@umcutrecht.nl; Andrzej Horban - ahorban@cdit-aids.med.pl; Klaus Korn - Klaus.Korn@viro.med.uni-
erlangen.de; Claudia Kücherer - KuechererC@rki.de; Thomas Leitner - tkl@lanl.gov; Clive Loveday - cloveday@doctors.org.uk; 
Eilidh MacRae - eilidh.macrae@icvc.org.uk; I Maljkovic-Berry - inam@lanl.gov; Laurence Meyer - meyer@vjf.inserm.fr; 
Claus Nielsen - cn@ssi.dk; Eline LM Op de Coul - Eline.op.de.Coul@rivm.nl; Vidar Ormaasen - vidar.ormaasen@ioks.uio.no; 
Luc Perrin - Luc.Perrin@hcuge.ch; Elisabeth Puchhammer-Stöckl - Elisabeth.puchhammer@meduniwien.ac.at; Lidia Ruiz - lruiz@irsicaixa.es; 
Mika O Salminen - Mika.salminen@ktl.fi; Jean-Claude Schmit - schmit.jc@chl.lu; Rob Schuurman - Rob.schuurman@lab.azu.nl; 
Vincent Soriano - vsoriano@dragonet.es; J Stanczak - jstanczak@cdit-aids.med.pl; Maja Stanojevic - mstanojevic@med.bg.ac.yu; 
Daniel Struck - struck.d@retrovirology.lu; Kristel Van Laethem - Kristel.vanlaethem@uz.kuleuven.ac.be; M Violin - claudia.balotta@unimi.it; 
Sabine Yerly - Sabine.Yerly@hcuge.ch; Maurizio Zazzi - zazzi@unisi.it; Charles A Boucher - c.boucher@erasmusmc.nl; Anne-
Mieke Vandamme - annemie.vandamme@uz.kuleuven.ac.be; the SPREAD Programme - dparask@cc.uoa.gr
* Corresponding author    
Abstract
Background: The prevalence and the origin of HIV-1 subtype B, the most prevalent circulating
clade among the long-term residents in Europe, have been studied extensively. However the spatial
diffusion of the epidemic from the perspective of the virus has not previously been traced.
Results: In the current study we inferred the migration history of HIV-1 subtype B by way of a
phylogeography of viral sequences sampled from 16 European countries and Israel. Migration
events were inferred from viral phylogenies by character reconstruction using parsimony. With
regard to the spatial dispersal of the HIV subtype B sequences across viral phylogenies, in most of
the countries in Europe the epidemic was introduced by multiple sources and subsequently spread
within local networks. Poland provides an exception where most of the infections were the result
of a single point introduction. According to the significant migratory pathways, we show that there
are considerable differences across Europe. Specifically, Greece, Portugal, Serbia and Spain, provide
sources shedding HIV-1; Austria, Belgium and Luxembourg, on the other hand, are migratory
targets, while for Denmark, Germany, Italy, Israel, Norway, the Netherlands, Sweden, Switzerland
and the UK we inferred significant bidirectional migration. For Poland no significant migratory
pathways were inferred.
Conclusion: Subtype B phylogeographies provide a new insight about the geographical
distribution of viral lineages, as well as the significant pathways of virus dispersal across Europe,
suggesting that intervention strategies should also address tourists, travellers and migrants.
Background
Pandemic HIV-1 group M infection originated in Africa
from the simian immunodeficiency virus (SIVcpz) infect-
ing chimpanzees [1-6]. The subtype B epidemic in the
United States and elsewhere, was the result of a single
point introduction -migration – of the virus from Haiti
around the late sixties [7,8]. The introduction of HIV-1
into Europe occurred mainly through homosexual con-
tacts or needle sharing in or from the USA [9-13], or
through heterosexual contacts with individuals from Cen-
tral Africa [14,15]. At the beginning of the HIV-1 epidemic
(the early 1980's) the prevalence of HIV-1 infection was
higher among men having sex with other men (MSM)
than among heterosexuals. For this reason and also
because subtype B was identified at a high prevalence
among MSM in the USA, it was the predominant clade in
Europe. The prevalence of non-B subtypes in Europe has
been increasing over the last years [16-31]. However, the
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dominated by viruses assigned to subtype B [32,33].
RNA viruses, such as the HIV-1, provide measurably
evolving populations characterized by very high nucle-
otide substitution rate [34,35]. Phylogenies can be used
for molecular epidemiology studies and notably they con-
tain information about temporal and spatial dynamics of
the virus [36]. The latter is the geographic pattern of viral
lineages sampled from different localities, also termed as
phylogeography, tracking the migration of the virus. For
several viral infections, the dispersal of the parasite and its
host cannot be easily tracked, therefore suggesting that
phylogenies may be a better way to monitor migratory
pathways of the virus [37,38]. This methodology has been
recently applied to phylogeographic studies of influenza A
(H5N1) [37] and HCV [39] epidemics showing the path-
ways of viral dispersal.
Thus, phylogenies are the 'state of the art' in characterizing
viral genealogy and evolution and also serve as tools to
track migration for organisms for which there is no other
way to monitor their dispersal [38]. Although several phy-
logenetic studies have analyzed HIV-1 clades by geo-
graphic region in Europe, none has inferred the history of
virus's migration through its phylogeny. In the present
study, we inferred the migration history of HIV-1 virus
among 17 countries in Europe, by way of a phylogeogra-
phy of subtype B sequences.
Results
Migration events were inferred through virus phylogenies
by using the Slatkin and Maddison's method [40] (illus-
trated in Figure 1). Trees were built by maximum likeli-
hood (ML) methodology and countries from which
sequences were sampled were assigned to the tips of the
103 ML bootstrap trees. Inclusion of a large number of
phylogenies takes into account phylogenetic uncertainty,
because migration events are estimated over a set of trees
rather than a single one.
Phylogenetic analyses
Phylogenies of subtype B sequences from 16 countries in
Europe and Israel (Table 1) showed no considerable
grouping of sequences by country, however in the case of
Poland most of the sequences (65, 72%) formed a single
monophyletic clade (Figure 2). Similarly a fraction of
sequences from Austria (16, 18%), Luxembourg (13,
14%) and Portugal (20, 22%) fell within single clusters,
however the number of viral lineages spreading within
local transmission networks was much lower in these
areas than in Poland. Notably, in Poland individuals
This tree contains 8 sequences sampled from 2 countries (A and B)Figure 1
This tree contains 8 sequences sampled from 2 coun-
tries (A and B). Tips (HIV-1 sequences) were labelled 
according to its sampling country. A. If there are no epidemi-
ological links between the two populations A and B, viral 
sequences will consist of two monophyletic groups, there-
fore representing distinct epidemics. B. In case that an indi-
vidual sampled within population B acquired the infection in 
geographic area A, one branch sampled from population B 
would cluster within the monophyletic clade of the popula-
tion A. The migration pattern for each country was esti-
mated by counting "state" (county label) changes at each 
internal node of the tree by the criterion of parsimony. For 
each country we counted "exporting" (From) and "import-
ing" (To) migration events. Specifically, as shown in Fig. 1b, a 
state change (A-B) is counted as an exporting migration 
event for country A and as importing for B. In our study 
migration events correspond to mobility of HIV-1 strains or 
infections and, therefore, inferred exporting or importing 
migration events are proportional to country-wise mobility 
of HIV-1 subtype B strains.Page 3 of 11
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phylogenetic methods were used to further confirm the
monophyletic nature of the B sequences from Poland,
Austria, Luxembourg and Portugal. The final analysis was
performed including a few sequences of the different
monophyletic clusters identified in the ML trees and 1–2
from the other countries as references. Sequences again
appeared as monophyletic in this analysis, with high pos-
terior probability support (>0.8; data not shown), further
supporting our previous results.
ML phylogenies suggest that sequences from the rest of
Europe show distinct grouping patterns. Specifically a
number of sequences for each locality cluster within short
monophyletic clades (approximately consisting of 2–6
sequences), or others show no grouping according to their
geographic origin (Figure 2E). These findings suggest that
except in the case of Poland and also to a lesser extend for
Austria, Portugal, Luxembourg, where a considerable per-
centage of infections were the result of single migration
and subsequent spread among the local population, for
the rest of countries there is a high level of mixing across
Europe.
For patients recruited in the prospective study, informa-
tion on the most likely origin of the HIV infection was col-
lected through a questionnaire. Among them, 572
sequences were used in the current analysis. Interestingly,
among those for whom this information was available
(456 patients), 90.4% claimed that they acquired the sub-
type B.
Statistical Phylogeography
To test the significance of specific pathways of location
changes (migration events) between countries, we esti-
mated the expected number of changes, under the null
hypothesis of complete geographic mixing, for each pair
of countries (Tables S1 and S2 in Additional file 1), as
described previously [37,39]. The total number of loca-
tion changes between countries (migration events) for all
trees was significantly lower than expected by chance
under the null hypothesis of panmixis confirming that,
although there is a high level of HIV dispersal between
countries, there is still geographic subdivision among the
subtype B lineages analyzed. Moreover, the results of this
test showed major differences across Europe (Additional
files 2 and 3). In particular, for Austria, Luxembourg and
Poland no significant exporting migration was observed,
while for the latter importing migration was also not sig-
nificant; therefore classifying Poland as the country with
the lowest HIV migration – or, in other words, with the
most isolated HIV epidemic among the countries ana-
lysed (Figure 3). For Austria, and Luxembourg, on the
other hand, there was evidence that some of the subtype
B infections were the result of migration from Italy and
Portugal, Switzerland, respectively; while similarly to
Poland no significant outgoing migration was observed.
According to the ML trees, only a few sequences from
Table 1: Proportion of transmission risk groups among the study population.
Risk groups
Country MSM IDUs Heterosexuals Others Unknown Sum
United Kingdom (GBR) 59 (66%) 0 (0%) 6 (7%) 0 (0%) 25 (28%) 90
Austria (AUT) 18 (20%) 5(6%) 7 (8%) 0 (0%) 60 (67%) 90
Belgium (BEL) 56 (65%) 3 (3%) 11 (13%) 4 (5%) 12 (14%) 86
Denmark (DNK) 15 (17%) 4 (4%) 7 (8%) 0 (0%) 64 (71%) 90
Spain (ESP) 46 (51%) 21 (23%) 17 (19%) 0 (0%) 6 (7%) 90
Germany (DEU) 85 (94%) 0 (0%) (0%) 0 (0%) 5 (6%) 90
Greece (GRC) 39 (53%) 3 (4%) 8 (11%) 1 (1%) 22 (30%) 73
Israel (ISR) 15 (44%) 8 (24%) 7 (21%) 1 (3%) 3 (9%) 34
Italy (ITA) 31 (34%) 15 (17%) 32 (36%) 0 (0%) 12 (13%) 90
Luxembourg (LUX) 50 (56%) 15 (17%) 19 (21%) 0 (0%) 6 (7%) 90
Netherlands (NLD) 57 (68%) 7 (8%) 15 (18%) 0 (0%) 5 (6%) 84
Norway (NOR) 19 (73%) 1 (4%) 5 (19%) 0 (0%) 1 (4%) 26
Poland (POL) 12 (13%) 42 (47%) 19 (21%) 0 (0%) 17 (19%) 90
Portugal (PRT) 27 (30%) 16 (18%) 35 (39%) 0 (0%) 12 (13%) 90
Serbia 22 (50%) 6 (14% 16 (36%) 0 (0%) 0 (0%) 44
Sweden (SWE) 44 (49%) 3 (3%) 10 (11%) 0 (0%) 33 (37%) 90
Switzerland (CHE) 48 (53%) 10 (11%) 28 (31%) 0 (0%) 4 (4%) 90
Sum 643 (48%) 159 (12%) 242 (18%) 6 (0.5%) 287 (21%) 1337Page 4 of 11
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cluster, suggesting limited migration to the latter coun-
tries (Figure 2D).
Germany, Greece, Italy, Norway, the Netherlands, Portu-
gal, Spain, Serbia, Switzerland, and the UK appeared as
source of subtype B mobility (high levels of exporting
migration; "From") to other countries (Additional files 2
and 3). In case that significant migration was detected
from a country to more than 2 others, the former was des-
ignated as "exporter". Notably, Greece's migratory targets
were dispersed to 7 countries, while for both Spain and
the Netherlands; they were to 5 and 6 countries, respec-
tively (Figure 3). High levels of HIV migration – with
regard to the highest difference between the observed and
the expected migration events under panmixis – were
detected from Italy to Austria and Switzerland, from Por-
tugal to Luxembourg and also from the Netherlands to
Germany (Table S2 in Additional file 1). On the other
hand, Belgium, Denmark, Sweden and Israel showed only
limited export of HIV-1 subtype B (Additional files 2 and
3).
Major migratory targets of HIV-1 subtype B (importing
migration; "To") were Austria, Belgium, Germany, Italy,
Luxembourg, Norway, the Netherlands, Sweden, Spain,
Switzerland, and the UK (a similar criterion as for the
"From" migration was used to assign countries) (Addi-
tional files 4 and 5), while limited migration was
observed into Serbia and Israel (Supplementary informa-
tion Figure 1c, d in Additional files 4 and 5) (in case that
significant migration was detected from a country to more
than 2 others, the former was designated as "exporter").
Notably, except from Poland, significant importing
migration was detected for all countries across Europe
(Figure 3).
Parts of the phylogenetic tree inferred for subtype B sequences sampled across EuropeFigure 2
Parts of the phylogenetic tree inferred for subtype B sequences sampled across Europe. Monophyletic groups of 
sequences sampled from A. Austria (purple), B. Portugal (cyan), C. Luxembourg (orange) and D. Poland (green). E. Part of the 
tree showing the geographical dispersal of HIV-1 subtype B sequences. Branches are shown in different colours by country of 
origin as described in the legend. Branches are not drawn to scale.Page 5 of 11
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persion was detected where Spain, Greece, Portugal and
Serbia acted as sources of migration events ("exporters")
(Figure 3); Austria, Belgium, and Luxembourg (Luxem-
bourg and Austria were classified within the "importers"
due to the high migration (>7) inferred from Portugal
towards Luxembourg), provided migratory targets
("importers") (Figure 3), while significant bidirectional
HIV migration was found for Denmark, Germany, Italy,
Israel, Norway, the Netherlands, Sweden, Switzerland and
the UK (Figure 3). Israel and Sweden were classified
among localities with bidirectional migration because in
both countries significant bidirectional mobility was
detected. In contrast, for Poland, no significantly import-
ing or exporting migration was found that is in accordance
with the high percentage of sequences grouping according
to the sampling location.
To further confirm our findings all steps of the analyses
(phylogenetic analysis with ML bootstrapping, inference
of migration events and statistical phylogeography) were
repeated in a 2nd run. Notably, migration events inferred
on 103 newly inferred ML bootstrap trees were almost
identical to the previous (R2 = 0.98, p < 0.001; data not
shown). Moreover, statistical phylogeography revealed
that out of 46 and 50 significantly high migration events
inferred in the two rounds of analyses, 43 were identical,
thus suggesting that the major migratory pathways were
reproducible.
Discussion
Our results based on a phylogeographic study of a large
number of sequences sampled from 16 countries in
Europe and Israel provided important clues about HIV-1
subtype B spatial diffusion across Europe. Notably accord-
ing to the findings of phylogenetic analyses, viral lineages
sampled from all countries except Poland, Austria, Lux-
embourg and Portugal, showed low levels of grouping
according to the geographic origin. For most countries, we
identified small networks of local transmission, but to a
different extent in each country, along with sequences
showing no particular geographic clustering. Such a pat-
tern suggests that the subtype B epidemic in most coun-
tries was introduced by several founders, some of them
causing subsequent local dispersal, while others lead to
dead end infections. We should note that under the con-
ditions of our study, we cannot estimate the percentage of
infections occurring within local transmission networks,
since we don't have sufficient covering per country.
Poland's epidemic dispersal is quite different. Based on
the high number of viral lineages coalescing to a common
origin within the country, we suggest that the epidemic is
the result of a few migrations of the virus successfully
spreading within the local population. This pattern is con-
sistent with a main viral dispersal through IDU networks
associated with extensive local epidemics. Monophyletic
HIV epidemics have been described among IDUs for other
European countries, as well, including also non-B sub-
types strains [12,13,26,27,42-45].
For Austria, Poland and Luxembourg we identified more
extensive local transmission networks than for the other
European countries. Similarly HIV local networks have
been described for Canada, Greece and the UK [46-50].
According to the epidemiological data, most of the sub-
type B infections newly diagnosed during 2002–2004,
occurred locally. The geographic distribution by means of
the viral evolutionary history, the phylogeography, on the
other hand, revealed high levels of viral dispersal. Both
observations are not necessarily in contradiction. Rather,
they suggest that most of the migration identified through
phylogeography may date from earlier in the transmission
chain, and that the pre-existing complexity of the epi-
demic (multiple sources of introduction from diverse
localities) is the main reason for the continuous extensive
geographical dispersal across the viral phylogeny. Particu-
larly if there are multiple founders, subsequent infections
will be dispersed, across the viral phylogeny, according to
the geographic origin of the founders' source. This is in
accordance with previous findings about multiple intro-
ductions of the subtype B infection through sexual inter-
courses or IDU across Europe [13,47,49,51,52].
In addition to epidemic dispersal patterns, our study pro-
vided important findings about HIV-1 subtype B major
sources and targets for migratory events, as well as locali-
ties with bidirectional viral dispersion.
In particular, Greece, Portugal, and Spain attract many
travellers and tourists, especially from Central Europe,
Significant HIV migratory pathways across EuropeFigure 3
Significant HIV migratory pathways across Europe. 
Arrowheads indicate the targets of migration shown in differ-
ent colours and styles by country of origin.Page 6 of 11
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tral Europe may, at least in part, occur by travellers




For countries classified among the HIV migratory targets
(Austria, Belgium and Luxembourg) the epidemic was
mainly imported due to the high HIV mobility to these
countries. According to the epidemiological information,
the highest rate of imported infections from other Euro-
pean countries occurs in Luxembourg. Moreover, the fact
that 13% of the population of Luxembourg is of Portu-
guese origin provides a plausible explanation for the
migratory pathway from Portugal http://www.migration
information.org/datahub. Another significant pathway
was tracked from Italy to Austria, in accordance with the
high influx from Italy during recent years http://
www.migrationinformation.org/datahub. Denmark pro-
vided migratory target from another Scandinavian coun-
try (Sweden) but also from Spain. This is in accordance
with epidemiological findings that a percentage of HIV
subtype B infections in Denmark originated from Sweden
and Spain.
Additionally we identified several countries showing bidi-
rectional migration. Notably, for the Netherlands 6 signif-
icant pathways were detected from and to the same
localities. The Netherlands is among the countries in
Europe with the most diverse geographical origin among
newly diagnosed patients, confirmed by the high percent-
age of non-Dutch individuals among the newly HIV-
infected patients during 2003–2004 [32,53]. Moreover,
because of its policies, the Netherlands attracts foreign
drug users and male homosexuals, two populations
known to be at higher risk for HIV infection [51].
Migratory pathways inferred through viral phylogenies
cannot be directly validated by other sources of informa-
tion (epidemiological figures, mobility and immigration
information, tourism, etc), because these data are not
stratified by subtype. Moreover, due to the high mobility
of population within Europe and the complexity of the
epidemic spread, information about the locus of infection
for an individual doesn't necessarily match with the geo-
graphic origin of the source. On the other hand, phyloge-
netic analysis of viral sequences provides a realistic
approach for the reconstruction of HIV transmission
chains or networks [36,46,47,49,54-56], therefore sug-
gesting that statistical phylogeography is appropriate for
inferring the spatial dispersal of a viral epidemic.
Given the high complexity of the epidemic, dense sam-
pling is needed in order to accurately reconstruct the spa-
tial characteristics of the subtype B infections in Europe.
This provides one of the limitations of this study; on the
other hand however the analysis of our dataset, which is
the largest available at the time of analysis, provides for a
first time a description of the geographic distribution of
viral lineages as well as the significant migrations of HIV
subtype B across Europe, by means of viral phylogenies.
Dense sampling for each locality would be ideal for such
purposes; however limited availability of sequences for
several countries, as well as computation time provide as
the major limitations for such a study.
We paid special attention to representativeness of our
data. The prospective SPREAD collection strategy (data
from 2002–2004) was specifically designed to avoid such
a bias [53], while the retrospectively collected CATCH
data (1996–2002) were sampled as part of national sur-
veillance studies designed to investigate the transmission
of drug resistance or as part of the standard clinical prac-
tice of baseline sequencing for all newly diagnosed cases
in each participating center [57]. For most countries
where national data were available, the data were a rather
good representation of the national epidemic.
In conclusion, HIV-1 subtype B phylogeographies provide
a new insight for the first time into the pathways of spatial
diffusion and virus migration across Europe. HIV-1 sub-
type B was each time introduced from multiple sources
and subsequently spread locally, but the pattern is not
uniform across Europe. The countries grouped into
sources (Greece, Portugal, Serbia and Spain) and sinks
(Austria, Belgium and Luxembourg) of virus migration, as
well as countries with significant bidirectional migration
(Denmark, Germany, Italy, Israel, Norway, the Nether-
lands, Sweden, Switzerland and the UK). The only excep-
tion was Poland where a significant number of sequences
fell within a monophyletic cluster. These results suggest
that mobility of the virus matches mobility of the host,
such that in order to reduce further spread of the epi-
demic, prevention measures should not only be directed
towards national populations, but also towards migrants,
travellers and tourists who are the major sources and tar-
gets of HIV dispersal.
Methods
HIV-1 sequences
Protease (PR) and partial reverse transcriptase (RT)
sequences were sampled from HIV-1 seropositive individ-
uals who had never received antiretroviral drugs (ARV) as
described previously [53,57]. Specifically, partial PR/RT
sequences were sampled from 17 countries in Europe
including Israel. Sequences were collected from two stud-
ies, the Combined Analysis of Resistance Transmission
over Time of Chronically and Acute Infected HIV Patients;
(CATCH), in a retrospective setting [57] and a prospective
study named after Strategy to Control SPREAD of HIV
Drug Resistance (SPREAD) [53]. In the CATCH analysisPage 7 of 11
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graphically distinct centres across the participating coun-
tries, except for Belgium and the Netherlands, where HIV-
1 sequences were sampled from a single geographic area.
In the prospective setting (SPREAD), samples were col-
lected during 2002–2004 according to two different
approaches in order to ensure representative sampling
[53]. Notably although data from the period 1996–2002
were retrospectively analyzed, they were collected as part
of national surveillance studies designed to investigate the
transmission of drug resistance or of the standard clinical
practice of baseline sequencing for all newly diagnosed
cases in each participating center [57]. In the prospective
setting a standardized sampling strategy was designed in
order to ensure representative sampling in all countries
[53]. For the purpose of this study we included only those
classified as subtype B. All individuals were sampled at a
single time point. The subtyping process was performed
by phylogenetic analysis [53,57]. The prevalence of the
transmission risk groups among the study population is
shown in Table 1.
Phylogenetic analyses
Sampling strategy
For the estimation of country-wise clustering (migration),
first we need to infer the phylogenies of the sequences
under study. One of the issues to be addressed was how
many sequences needed to be included for each country.
The dataset size needs to be large enough as: 1) to include
most of the available information from each country and
2) to estimate rare migration events. On the other hand,
we had to restrict the number of sequences to keep the
computation time needed for phylogenetic inference rea-
sonable, while maintaining an informative number of
sequences required for the calculation of migration
events. For this reason, we performed a preliminary anal-
ysis of migration for 4 countries including 10, 20 25 or 90
sequences per country. For each dataset, we tested
whether the distribution of the total number of migration
events across the set of all credible trees differed signifi-
cantly from a distribution of randomly generated trees
(phylogenetic inference was performed by ML method).
The results of this preliminary analysis showed that with
25 sequences per country, the largest number of countries
reached significantly different migration levels than com-
pared to the distribution for a random set of trees (P <
0.01). However the larger the number of sequences
included per country the higher the signal for clustering
with regard the total number of changes across inferred
versus random set of trees.
Consequently, we included in the analyses the largest
number of sequences (90) available per country, expect
from Belgium, Greece, the Netherlands, Israel, Norway
and Serbia for which a smaller number of sequences was
available, however only for the last three countries the
number of sequences included was << 90. As a result of
choosing approximately equal number of strains per
country, irrespective of the prevalence or the total number
of infected individuals across Europe, we calculated the
relative mobility per infected individual. Therefore, the
numbers in the migration matrices are directly compara-
ble reflecting actual differences in mobility between coun-
tries. For example, we estimated higher migration from
the UK to Spain (5.34), than from Germany to Italy (3.23)
(Table S2 in Additional file 1).
Phylogenetic analyses for the estimation of the migration
process were performed in a single dataset consisting of
1337 sequences analyzed in two independent runs (Table
1).
Alignment and phylogenetic tree reconstruction
The alignment of the subtype B partial RT sequences sam-
pled from 1337 individuals was performed using CLUS-
TAL W version 1.74 [58] and manually edited according
to the encoded reading frame. In order to avoid any bias
due to convergent evolution at antiretroviral drug resist-
ance mutations on the phylogenetic analysis, we excluded
all sites associated with major resistance in PR (30, 32, 33,
46, 47, 48, 50, 54, 76, 82, 84, 88, and 90) and RT (41, 62,
65, 67, 69, 70, 74, 75, 77, 100, 103, 106,108, 115, 116,
151, 181, 184, 188, 190, 210, 215, 219, 225, and 236)
leaving 687 nt.
Phylogenetic trees were inferred by maximum likelihood
method under the general time-reversible GTR model of
nucleotide substitution including a Γ distributed rates
heterogeneity among sites as implemented in RAxML
[59]. Bootstrapping was performed on the maximum like-
lihood trees (1000 replicates) to assess the reliability of
the obtained topologies.
Inference of migration events
All bootstrap generated trees (103) were used for the esti-
mation of the HIV-1 migration events by using the cladis-
tic approach first described by Slatkin and Maddison [40],
as implemented in MacClade [60]. Specifically, all the
nodes of the inferred trees were assigned with a character
according to the geographic origin (e.g. 0, 1, 2, 3 for Aus-
tria, Belgium, Denmark, France, etc). The algorithm
reconstructs "ancestral" states that in our case correspond
to countries, at each internal node by the criterion of par-
simony [40]. Parsimony selects the reconstruction that
minimizes the total number of steps on the tree [41].
When two branches from 2 different locations (e.g. 0 and
1) join with each other, and thus more than one character
can be reconstructed at the node, then the ancestor state at
the internal node is assigned to be the union of the twoPage 8 of 11
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number between two groups of sequences remains low,
the possibility for migration events between these partic-
ular groups also remains low.
Specifically, the migration events between HIV-1
sequences sampled in different locations were estimated
for each dataset according to the following method: 1) for
nodes with more than one equally parsimonious recon-
structions (e.g. 0, 1 or 0), implicit examination of all most
parsimonious reconstructions (MPRs) was used in case of
a big number of MPRs [61,62], while explicit examination
was used in case of a small number of MPR, as imple-
mented in MacClade. As a result, for a particular type of
character change, e.g. [0,1] MacClade reports a minimum,
a maximum and a average number of [0,1] changes esti-
mated over all possible MPRs. We estimated the average
number of migration events for each tree used in the anal-
yses. 2) Polytomies that correspond to nodes with more
than two descendant nodes were interpreted as regions of
uncertain evolution (soft polytomies) as implemented in
MacClade.
Inference of migration matrices
For each dataset a 17 × 17 migration matrix was estimated
between HIV-1 sequences sampled in different European
countries. Each migration event was calculated as the
median of the distribution estimated from all trees (103)
used in the analysis. In the matrix, all 'from' events and 'to'
events are pooled per country.
Statistical phylogeography
To further estimate which migration events were signifi-
cantly different from the expected number of changes
under the null hypothesis of full geographic mixing of
HIV-1 sequences, we estimated if the distribution for each
of the migration events estimated over 103 bootstrap trees
was statistically different from the distribution estimated
from the same set of trees (103) after reshuffling taxa at the
tips. This analysis was performed using Mesquite [63].
Equality of medians between observed and expected
migration events was assessed by means of the Kruskal-
Wallis one-way analysis of variance and the level of signif-
icance was adjusted according to Bonferroni correction for
multiple comparisons.
The differences between the observed and the expected
values indicate the levels of HIV-1 country-dependent
structure in the dataset, and thus also of the relative
mobility of the virus between countries. This strategy
allowed estimating significant differences also when an
unequal number of strains were included per country.
Notably in order to assess the validity of our results, the
whole process of phylogenetic analysis, inference of
migration events and statistical phylogeography was
repeated twice.
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Tables S1 and S2. Table S1 – Number of calculated migration events 
(medians) between countries. Table S2 – Differences of the medians 
between observed and the expected migration events. Cells in bold and 
underlined bold denote significantly higher and lower migration numbers, 
respectively.




Figure S1 (part A). Significant HIV exporting (A and B) and importing 
(C and D) migration events between different countries as estimated by 
statistical phylogeography study For all countries, 90 sequences were 
included per analysis, except for Belgium (BEL), Greece (GRC) and the 
Netherlands (NLD) for which 86, 73 and 84 sequences were included. 
For Israel (ISR), Norway (NOR) and Serbia (YUG) <<< 90 sequences 
were available, respectively. This lower number of sequences explains why 
the significantly high migration count for these countries is lower than for 
the other countries. Country code as in table 1.




Figure S1 (part B). Significant HIV exporting (A and B) and importing 
(C and D) migration events between different countries as estimated by 
statistical phylogeography study For all countries, 90 sequences were 
included per analysis, except for Belgium (BEL), Greece (GRC) and the 
Netherlands (NLD) for which 86, 73 and 84 sequences were included. 
For Israel (ISR), Norway (NOR) and Serbia (YUG) <<< 90 sequences 
were available, respectively. This lower number of sequences explains why 
the significantly high migration count for these countries is lower than for 
the other countries. Country code as in table 1.
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